Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma

Yang Jun Kang; Byung Chan Lee; Jae Kyu Kim; Nam Yeol Yim; Hyoung Ook Kim; Soo Buem Cho; Yong Yeon Jeong

doi:10.1007/s00270-019-02349-9

Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma

Yang Jun Kang, Byung Chan Lee, Jae Kyu Kim, Nam Yeol Yim, Hyoung Ook Kim, Soo Buem Cho, Yong Yeon Jeong

Department of Radiology

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Purpose: Approximately, 60–70% of patients with early-stage hepatocellular carcinoma (HCC) globally are ineligible for the recommended first-line procedures. This study aimed to compare conventional transcatheter arterial chemoembolization (cTACE) with a treatment, small drug-eluting bead TACE (DEB-TACE), in patients with stage 0/A HCCs. Materials and Methods: We retrospectively investigated 76 patients who underwent first-time cTACE (n = 40) or DEB-TACE using 75–150 µm DC Beads^® (n = 36) for Barcelona Clinic Liver Cancer (BCLC) stage 0/A HCC < 3 cm at a single tertiary care center between July 2015 and March 2017. Outcome measurements were time to local progression (assessed per modified response evaluation criteria in solid tumors), tumor response at one month and intrahepatic distal recurrence, progression-free survival, overall survival, safety, and toxicity. Results: The study included 60 (78%) men and 16 (21%) women; participant mean age was 65.8 years. Objective response rates between the cTACE and DEB-TACE groups were similar (p > 0.05). Complete and partial 1-month tumor response rates were 60.0% and 22.5%, respectively, in the cTACE group and 69.4% and 25.0%, respectively, in the DEB-TACE group. The abdominal pain grade was significantly lower with DEB-TACE than with cTACE (p = 0.001). AST and ALT levels after tumor treatment with DEB-TACE were significantly lower than those after treatment with cTACE (p = 0.018 and 0.006). Time to local progression, intrahepatic distal recurrence, progression-free survival, and overall survival were not significantly between the DEB-TACE group and the cTACE group (p > 0.05). Conclusion: Time to local progression between groups was not significantly different; however, post-embolic syndrome occurred less frequently in the DEB-TACE group. DEB-TACE appears to be a feasible treatment for small HCCs. Level of Evidence: Level 3.

Original language	English
Pages (from-to)	55-64
Number of pages	10
Journal	CardioVascular and Interventional Radiology
Volume	43
Issue number	1
DOIs	https://doi.org/10.1007/s00270-019-02349-9
State	Published - 1 Jan 2020

Bibliographical note

Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Keywords

Adverse event
Conventional transcatheter arterial chemoembolization
Drug-eluting bead transcatheter arterial chemoembolization
Drug-eluting beads
Hepatocellular carcinoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00270-019-02349-9

Cite this

@article{0f1a2c2b65504250a3a4b6f219f2e6a1,

title = "Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma",

abstract = "Purpose: Approximately, 60–70% of patients with early-stage hepatocellular carcinoma (HCC) globally are ineligible for the recommended first-line procedures. This study aimed to compare conventional transcatheter arterial chemoembolization (cTACE) with a treatment, small drug-eluting bead TACE (DEB-TACE), in patients with stage 0/A HCCs. Materials and Methods: We retrospectively investigated 76 patients who underwent first-time cTACE (n = 40) or DEB-TACE using 75–150 µm DC Beads{\textregistered} (n = 36) for Barcelona Clinic Liver Cancer (BCLC) stage 0/A HCC < 3 cm at a single tertiary care center between July 2015 and March 2017. Outcome measurements were time to local progression (assessed per modified response evaluation criteria in solid tumors), tumor response at one month and intrahepatic distal recurrence, progression-free survival, overall survival, safety, and toxicity. Results: The study included 60 (78%) men and 16 (21%) women; participant mean age was 65.8 years. Objective response rates between the cTACE and DEB-TACE groups were similar (p > 0.05). Complete and partial 1-month tumor response rates were 60.0% and 22.5%, respectively, in the cTACE group and 69.4% and 25.0%, respectively, in the DEB-TACE group. The abdominal pain grade was significantly lower with DEB-TACE than with cTACE (p = 0.001). AST and ALT levels after tumor treatment with DEB-TACE were significantly lower than those after treatment with cTACE (p = 0.018 and 0.006). Time to local progression, intrahepatic distal recurrence, progression-free survival, and overall survival were not significantly between the DEB-TACE group and the cTACE group (p > 0.05). Conclusion: Time to local progression between groups was not significantly different; however, post-embolic syndrome occurred less frequently in the DEB-TACE group. DEB-TACE appears to be a feasible treatment for small HCCs. Level of Evidence: Level 3.",

keywords = "Adverse event, Conventional transcatheter arterial chemoembolization, Drug-eluting bead transcatheter arterial chemoembolization, Drug-eluting beads, Hepatocellular carcinoma",

author = "Kang, {Yang Jun} and Lee, {Byung Chan} and Kim, {Jae Kyu} and Yim, {Nam Yeol} and Kim, {Hyoung Ook} and Cho, {Soo Buem} and Jeong, {Yong Yeon}",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).",

year = "2020",

month = jan,

day = "1",

doi = "10.1007/s00270-019-02349-9",

language = "English",

volume = "43",

pages = "55--64",

journal = "CardioVascular and Interventional Radiology",

issn = "0174-1551",

publisher = "Springer",

number = "1",

}

Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. / Kang, Yang Jun; Lee, Byung Chan; Kim, Jae Kyu et al.
In: CardioVascular and Interventional Radiology, Vol. 43, No. 1, 01.01.2020, p. 55-64.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma

AU - Kang, Yang Jun

AU - Lee, Byung Chan

AU - Kim, Jae Kyu

AU - Yim, Nam Yeol

AU - Kim, Hyoung Ook

AU - Cho, Soo Buem

AU - Jeong, Yong Yeon

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Purpose: Approximately, 60–70% of patients with early-stage hepatocellular carcinoma (HCC) globally are ineligible for the recommended first-line procedures. This study aimed to compare conventional transcatheter arterial chemoembolization (cTACE) with a treatment, small drug-eluting bead TACE (DEB-TACE), in patients with stage 0/A HCCs. Materials and Methods: We retrospectively investigated 76 patients who underwent first-time cTACE (n = 40) or DEB-TACE using 75–150 µm DC Beads® (n = 36) for Barcelona Clinic Liver Cancer (BCLC) stage 0/A HCC < 3 cm at a single tertiary care center between July 2015 and March 2017. Outcome measurements were time to local progression (assessed per modified response evaluation criteria in solid tumors), tumor response at one month and intrahepatic distal recurrence, progression-free survival, overall survival, safety, and toxicity. Results: The study included 60 (78%) men and 16 (21%) women; participant mean age was 65.8 years. Objective response rates between the cTACE and DEB-TACE groups were similar (p > 0.05). Complete and partial 1-month tumor response rates were 60.0% and 22.5%, respectively, in the cTACE group and 69.4% and 25.0%, respectively, in the DEB-TACE group. The abdominal pain grade was significantly lower with DEB-TACE than with cTACE (p = 0.001). AST and ALT levels after tumor treatment with DEB-TACE were significantly lower than those after treatment with cTACE (p = 0.018 and 0.006). Time to local progression, intrahepatic distal recurrence, progression-free survival, and overall survival were not significantly between the DEB-TACE group and the cTACE group (p > 0.05). Conclusion: Time to local progression between groups was not significantly different; however, post-embolic syndrome occurred less frequently in the DEB-TACE group. DEB-TACE appears to be a feasible treatment for small HCCs. Level of Evidence: Level 3.

AB - Purpose: Approximately, 60–70% of patients with early-stage hepatocellular carcinoma (HCC) globally are ineligible for the recommended first-line procedures. This study aimed to compare conventional transcatheter arterial chemoembolization (cTACE) with a treatment, small drug-eluting bead TACE (DEB-TACE), in patients with stage 0/A HCCs. Materials and Methods: We retrospectively investigated 76 patients who underwent first-time cTACE (n = 40) or DEB-TACE using 75–150 µm DC Beads® (n = 36) for Barcelona Clinic Liver Cancer (BCLC) stage 0/A HCC < 3 cm at a single tertiary care center between July 2015 and March 2017. Outcome measurements were time to local progression (assessed per modified response evaluation criteria in solid tumors), tumor response at one month and intrahepatic distal recurrence, progression-free survival, overall survival, safety, and toxicity. Results: The study included 60 (78%) men and 16 (21%) women; participant mean age was 65.8 years. Objective response rates between the cTACE and DEB-TACE groups were similar (p > 0.05). Complete and partial 1-month tumor response rates were 60.0% and 22.5%, respectively, in the cTACE group and 69.4% and 25.0%, respectively, in the DEB-TACE group. The abdominal pain grade was significantly lower with DEB-TACE than with cTACE (p = 0.001). AST and ALT levels after tumor treatment with DEB-TACE were significantly lower than those after treatment with cTACE (p = 0.018 and 0.006). Time to local progression, intrahepatic distal recurrence, progression-free survival, and overall survival were not significantly between the DEB-TACE group and the cTACE group (p > 0.05). Conclusion: Time to local progression between groups was not significantly different; however, post-embolic syndrome occurred less frequently in the DEB-TACE group. DEB-TACE appears to be a feasible treatment for small HCCs. Level of Evidence: Level 3.

KW - Adverse event

KW - Conventional transcatheter arterial chemoembolization

KW - Drug-eluting bead transcatheter arterial chemoembolization

KW - Drug-eluting beads

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85074583554&partnerID=8YFLogxK

U2 - 10.1007/s00270-019-02349-9

DO - 10.1007/s00270-019-02349-9

M3 - Article

C2 - 31646378

AN - SCOPUS:85074583554

SN - 0174-1551

VL - 43

SP - 55

EP - 64

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

IS - 1

ER -

Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this